chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 43.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Headache, Nausea, Pyrexia
Clinical narrative: Severe headache; Chills; Fever (fever dropped after 2 days); Nausea; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 02Apr2021 at 14:00 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history included appendectomy. The patient had no known allergies to medications, food or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received unspecified concomitant medications. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the left arm on 12Mar2021 at 14:30 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. On 03Apr2021 at 03:00, the patient experienced severe headache, chills, fever and nausea which lasted about 4-5 days (fever dropped after 2 days). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events severe headache, chills, fever (fever dropped after 2 days) and nausea was resolved on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Oral herpes
Clinical narrative: With both vaccines around 2 days later got two cold sores with each; This is a spontaneous report from a contactable nurse, the patient. A 24-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 09Mar2021 at 15:00 (at the age of 24-years-old) and also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 06Apr2021 at 15:00 (at the age of 24-years-old) as a single dose for COVID-19 immunisation. Medical history included Attention Deficit Hyperactivity Disorder (ADHD) and migraines. The patient had no known allergies to medications, food, or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included lisdexamfetamine mesilate (VYVANSE) and spironolactone (MANUFACTURER UNKNOWN), both taken for an unspecified indication from an unknown date and unknown if ongoing. On 11Mar2021 at 13:00 and 08Apr2021, two days after the administration of both the doses, the patient got two cold sores with each. She did not have a break out in over two years and had been very careful and kept her schedule/diet/health the same. The one difference both times was with the vaccine. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the event and included treatment with valacyclovir (MANUFACTURER UNKNOWN) medication. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event cold sores was recovering at the time of report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Agitation, Chills, Fatigue, Headache, Nausea
Clinical narrative: Severe chills; Fever; Extreme nausea; Headache; Severe body aches; Agitation; Extreme fatigue; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 23Apr2021 at 14:30 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included loratadine (CLARITIN) for allergies from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 02Apr2021 at 14:30 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. On 24Apr2021 at 01:30, the patient experienced severe chills, fever, extreme nausea, headache, severe body aches, agitation and extreme fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event severe chills, fever, extreme nausea, headache, severe body aches, agitation and extreme fatigue was recovering at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia
Clinical narrative: Severe chills; Fever; Extreme nausea; Headache; Severe body aches; Agitation; Extreme fatigue; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 23Apr2021 at 14:30 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included loratadine (CLARITIN) for allergies from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 02Apr2021 at 14:30 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. On 24Apr2021 at 01:30, the patient experienced severe chills, fever, extreme nausea, headache, severe body aches, agitation and extreme fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event severe chills, fever, extreme nausea, headache, severe body aches, agitation and extreme fatigue was recovering at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration, Rash pruritic
Clinical narrative: Dose 1:10Mar2021, Dose2: 26Mar2021 (duration between the doses is 16 days); Itchy rash from injection site to elbow; This is a spontaneous report from a non-contactable consumer, the patient. A 62-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 26Mar2021 (at the age of 62-years-old) as a single dose for COVID-19 immunisation (inappropriate schedule of vaccine administered). Medical history was included known allergy to penicillin. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included escitalopram oxalate (LEXAPRO), for an unknown indication from an unknown date and unknown if ongoing.  The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 10Mar2021 at 08:30 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. On 28Mar2021 within couple of days, the patient experienced itchy rash from injection site to elbow which lasted for 2 weeks. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events.  Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event, itchy rash from injection site to elbow was resolved on an unknown date in Apr 2021.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: Gait inability, Muscle spasms
Clinical narrative: Severe leg cramping; So bad could not walk; This is a spontaneous report from a contactable consumer, the patient. A 76-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 16Apr2021 at 13:45 (at the age of 76-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not take any concomitant medications. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received rosuvastatin calcium (CRESTOR) for unknown indication on an unknown date and experienced drug allergy. On 16Apr2021 at 17:00, the patient experienced severe leg cramping, so bad could not walk. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events which included unspecified medication for muscle spasms. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events severe leg cramping, so bad could not walk was resolved on an unknown date in Apr2021.    No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: Rash appeared from both wrists to about half of the arm. It doesn't hurt or itchy.; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0151) via an unspecified route of administration in the left arm on 19Apr2021 at 15:30 (at the age of 60-year-old) as a single dose for COVID-19 immunisation. Medical history included graves' disease and penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included hydrochlorothiazide, losartan potassium (LOSARTAN/HCTZ) and thiamazole (METHIMAZOLE) for an unknown indication on an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6204) via an unspecified route of administration in the left arm on 22Mar2021 at 15:00 (at the age of 60-year-old) as a single dose for COVID-19 immunisation. Since the vaccination, the patient had not been tested for COVID-19. On 22Apr2021, the patient experienced rash which appeared from both wrists to about half of the arm. It didn't hurt or itchy. The clinical outcome of the event rash appeared from both wrists to about half of the arm. It didn't hurt or itchy was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Pain, Pyrexia, Vaccination site pruritus
Clinical narrative: Itching of the injection site; Severe headache; Fever; Body aches; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0162) via an unspecified route of administration in the left arm on 16Apr2021 at 14:45 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 on an unknown date. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any medication within 2 weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 26Mar2021 at 15:30 (at the age of 35-years-old) as a single dose for COVID-19 immunisation.  On 17Apr2021 at 00:00, the patient experienced itching of the injection site, severe headache, fever and body aches. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events itching of the injection site, severe headache, fever, body aches were not recovered at the time of report.  No follow-up attempts are needed. No further information is expected.
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Hypoaesthesia, Pallor, Paraesthesia
Clinical narrative: both hands were red; both hands were very pale white; Both hands felt very numb; Both hands were tingling; This is a spontaneous report from a contactable consumer, the patient. A 28-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 21Apr2021 at 10:45 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. Medical history included gilberts syndrome 10 years ago and had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included acetylsalicylic acid(ALKA SELTZER) from an unknown date for an unknown indication and unknown if ongoing. On 24Apr2021 at 07:00 the patients both hands were red and very pale white, felt very numb and tingling. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of reported events which included treatment with anti inflammatory drugs.  Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events both hands were red and very pale white, felt very numb and tingling were not resolved at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Migraine, Myalgia
Clinical narrative: Extreme migraine; Muscle aches; This is a spontaneous report from a non-contactable consumer, the patient. A 41-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the left arm on 19Apr2021 at 13:30 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. On 19Apr2021 at 20:00, the patient experienced extreme migraine and muscle aches. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events extreme migraine and muscle aches was not recovered at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Tinnitus
Clinical narrative: "I" began tinnitus in "my" right ear and dizziness.; "I" began tinnitus in "my" right ear and dizziness.; This is a spontaneous report from a non-contactable consumer, the patient. A 54-year-old female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 09Apr2021 (at the age of 54-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient had no known allergies to medications, food, or other products. concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. On 10Apr2021, the day after her second dose of the vaccine, the patient experienced tinnitus in her right ear and dizziness. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events tinnitus in her right ear and dizziness was not resolved at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Axillary mass, Lymphadenopathy
Clinical narrative: A swollen, sore spot appeared in the left armpit; Large and painful swollen lymph node; This is a spontaneous report from a contactable consumer, the patient. A 26-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 09Apr2021 at 11:45 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any concomitant medication within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 12Apr2021, days after receiving vaccination, the patient experienced a swollen, sore spot that appeared in the left armpit. It was reported that the spot had continued to swell, and it was then very, very painful and continued to grow and it was then nearly the size of half a golf ball.  She had been told that it looked like a swollen lymph node, but was shocked at how large and painful it was. The fact that it continued to grow in size concerned her. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the events a swollen, sore spot appeared in the left armpit was and large and painful swollen lymph node was not resolved at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Ears have been ringing loudly 24 hours a day; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 25Mar2021 at 12:00 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to penicillin. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included bupropion hydrochloride (WELLBUTRIN), ibuprofen (ADVIL) and diphenhydramine hydrochloride (BENADRYL); all for unknown indications from unknown dates and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 25Mar2021 at 20:00, the patient's ears had been ringing loudly 24 hours a day. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event ears have been ringing loudly 24 hours a day was not resolved at the time of the report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Dizziness, Electric shock sensation, Feeling abnormal, Movement disorder
Clinical narrative: Extreme vertigo; Debilitating; Dizziness; Feels like electrical zaps in my brain; Difficult to think clearly or move; Difficult to think clearly or move; This is a spontaneous report from a contactable consumer, the patient. A 23-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 03Apr2021 at 10:00 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. Medical history included anxiety and attention deficit-hyperactivity disorder (ADHD). The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medications. On 04Apr2021 at 08:00, the patient experienced extreme vertigo, debilitating dizziness-feels like electrical zaps in brain that make it difficult to think clearly or move. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events extreme vertigo, debilitating dizziness-feels like electrical zaps in brain that make it difficult to think clearly or move were not resolved.  No follow-up attempts are possible. No further information is expected.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Vertigo
Clinical narrative: Extreme vertigo; Debilitating; Dizziness; Feels like electrical zaps in my brain; Difficult to think clearly or move; Difficult to think clearly or move; This is a spontaneous report from a contactable consumer, the patient. A 23-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 03Apr2021 at 10:00 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. Medical history included anxiety and attention deficit-hyperactivity disorder (ADHD). The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medications. On 04Apr2021 at 08:00, the patient experienced extreme vertigo, debilitating dizziness-feels like electrical zaps in brain that make it difficult to think clearly or move. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events extreme vertigo, debilitating dizziness-feels like electrical zaps in brain that make it difficult to think clearly or move were not resolved.  No follow-up attempts are possible. No further information is expected.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Rash, Vaccination site rash
Clinical narrative: Itchy rash at the injection site; Another rash about an inch away from the main site; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8735,) via an unspecified route of administration in the left arm on 15Apr2021 at 10:00 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN) for an unknown indication from an unknown date and unknown if ongoing. On 15Apr2021 at 22:00, about 12 hours after the vaccination, the patient experienced itchy rash at the injection site and also another rash about an inch away from the main site. The reaction happened about 12 hours after receiving the injection and lasted about 5 days. The patient was wondering if a worse rash could happen when she gets the second shot. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event itchy rash at the injection site and another rash about an inch away from the main site were resolved on 20Apr2021 after a duration of about 5 days.  No follow-up attempts are needed. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Fatigue, Headache, Myalgia, Nausea
Clinical narrative: Sore arm; Nausea; Fatigue; Muscle aches; Fever; Sore throat; Headache; Dizziness; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the arm right on 19Apr2021 at 14:45 (at the age of 30-year-old) as a single dose for COVID-19 immunisation. Medical history included crohn's disease, panic disorder and penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included ustekinumab (STELARA), alprazolam (XANAX) and ritual vitamins (MANUFACTURER UNKNOWN); all for an unknown indication from an unknown date and unknown if ongoing. The patient previously received clindamycin palmitate hydrochloride (CLINDAMYCIN) and ceftriaxone sodium (ROCEPHIN) and experienced drug allergy. The patient previously received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the right arm on 24Mar2021 at 15:45 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. On 19Apr2021 at 16:00, the patient experienced sore arm, nausea, fatigue, muscle aches, fever, sore throat, headache and dizziness. The events did not result in a visit to the doctors or other healthcare professional office/clinic, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events sore arm, nausea, fatigue, muscle aches, fever, sore throat, headache and dizziness was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Oropharyngeal pain, Pain in extremity, Pyrexia
Clinical narrative: Sore arm; Nausea; Fatigue; Muscle aches; Fever; Sore throat; Headache; Dizziness; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the arm right on 19Apr2021 at 14:45 (at the age of 30-year-old) as a single dose for COVID-19 immunisation. Medical history included crohn's disease, panic disorder and penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included ustekinumab (STELARA), alprazolam (XANAX) and ritual vitamins (MANUFACTURER UNKNOWN); all for an unknown indication from an unknown date and unknown if ongoing. The patient previously received clindamycin palmitate hydrochloride (CLINDAMYCIN) and ceftriaxone sodium (ROCEPHIN) and experienced drug allergy. The patient previously received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the right arm on 24Mar2021 at 15:45 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. On 19Apr2021 at 16:00, the patient experienced sore arm, nausea, fatigue, muscle aches, fever, sore throat, headache and dizziness. The events did not result in a visit to the doctors or other healthcare professional office/clinic, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events sore arm, nausea, fatigue, muscle aches, fever, sore throat, headache and dizziness was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Dizziness, Fatigue, Headache
Clinical narrative: Strong headache; Muscle pain; Dizzing; arm pain; chills; join pain; nausea; tiredness; rash; itching; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the arm left on 17Apr2021 at 14:00 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. The patient's medical history and known allergies were reported as n/a. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The concomitant medications included fish oil (OMEGA 3), ascorbic acid (VITAMIN C) and zinc (MANUFACTURER UNKNOWN),all for unknown indications from unknown dates and unknown if ongoing. On 18Apr2021 at 01:00, the patient experienced chills, nausea, strong headache, muscle pain, dizzing, arm pain, join pain, tiredness, rash and itching. On 20Apr2021, the patient underwent SARS-CoV-2 nasal swab test and the result was unknown. The adverse events did not result in doctor or other health care professional office/clinic visit and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events chills, nausea, strong headache, muscle pain, dizzing, arm pain, join pain, tiredness, rash and itching were resolving at the time of this report.    No follow-up attempts are needed. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Nausea, Pain in extremity, Pruritus, Rash
Clinical narrative: Strong headache; Muscle pain; Dizzing; arm pain; chills; join pain; nausea; tiredness; rash; itching; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the arm left on 17Apr2021 at 14:00 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. The patient's medical history and known allergies were reported as n/a. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The concomitant medications included fish oil (OMEGA 3), ascorbic acid (VITAMIN C) and zinc (MANUFACTURER UNKNOWN),all for unknown indications from unknown dates and unknown if ongoing. On 18Apr2021 at 01:00, the patient experienced chills, nausea, strong headache, muscle pain, dizzing, arm pain, join pain, tiredness, rash and itching. On 20Apr2021, the patient underwent SARS-CoV-2 nasal swab test and the result was unknown. The adverse events did not result in doctor or other health care professional office/clinic visit and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events chills, nausea, strong headache, muscle pain, dizzing, arm pain, join pain, tiredness, rash and itching were resolving at the time of this report.    No follow-up attempts are needed. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: SARS-CoV-2 test
Clinical narrative: Strong headache; Muscle pain; Dizzing; arm pain; chills; join pain; nausea; tiredness; rash; itching; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the arm left on 17Apr2021 at 14:00 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. The patient's medical history and known allergies were reported as n/a. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The concomitant medications included fish oil (OMEGA 3), ascorbic acid (VITAMIN C) and zinc (MANUFACTURER UNKNOWN),all for unknown indications from unknown dates and unknown if ongoing. On 18Apr2021 at 01:00, the patient experienced chills, nausea, strong headache, muscle pain, dizzing, arm pain, join pain, tiredness, rash and itching. On 20Apr2021, the patient underwent SARS-CoV-2 nasal swab test and the result was unknown. The adverse events did not result in doctor or other health care professional office/clinic visit and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events chills, nausea, strong headache, muscle pain, dizzing, arm pain, join pain, tiredness, rash and itching were resolving at the time of this report.    No follow-up attempts are needed. No further information is expected.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Decreased appetite, Gait inability, Headache
Clinical narrative: Extreme headache; Nausea; Fever; Chills; Sweating; Pain in joints; Hurt to touch skin anywhere; Total loss of appetite; Could not walk without help; This is a spontaneous report from a contactable consumer, the patient. A 70-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 15Apr2021 at 17:00 (at the age of 70-year-old), as a single dose for COVID-19 immunisation. Medical history included known allergy to sulpha. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN) for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: E?8732) via an unspecified route of administration in the left arm on 26Mar2021 at 18:00 (at the age of 70-year-old), as a single dose for COVID-19 immunisation. On 16Apr2021 at 06:00, the patient experienced extreme headache, nausea, fever, chills, sweating, pain in joins, hurt to touch skin anywhere, total loss of appetite and could not walk without help. The patient also reported that, pain was worse on skin than any pain she has ever had in her life. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events extreme headache, nausea, fever, chills, sweating, pain in joins, hurt to touch skin anywhere, total loss of appetite and could not walk without help was resolved on an unknown date in Apr2021.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Hyperhidrosis, Nausea, Pain of skin, Pyrexia
Clinical narrative: Extreme headache; Nausea; Fever; Chills; Sweating; Pain in joints; Hurt to touch skin anywhere; Total loss of appetite; Could not walk without help; This is a spontaneous report from a contactable consumer, the patient. A 70-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 15Apr2021 at 17:00 (at the age of 70-year-old), as a single dose for COVID-19 immunisation. Medical history included known allergy to sulpha. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN) for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: E?8732) via an unspecified route of administration in the left arm on 26Mar2021 at 18:00 (at the age of 70-year-old), as a single dose for COVID-19 immunisation. On 16Apr2021 at 06:00, the patient experienced extreme headache, nausea, fever, chills, sweating, pain in joins, hurt to touch skin anywhere, total loss of appetite and could not walk without help. The patient also reported that, pain was worse on skin than any pain she has ever had in her life. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events extreme headache, nausea, fever, chills, sweating, pain in joins, hurt to touch skin anywhere, total loss of appetite and could not walk without help was resolved on an unknown date in Apr2021.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Flushing, Palpitations
Clinical narrative: Flushing of the face; Sudden racing heart; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE;Lot Number: ER8731) via an unspecified route of administration in the left arm on 13Apr2021 at 17:45 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. Medical history included rheumatoid arthritis. Prior to the vaccination, the patient was not diagnosed with COVID-19.Concomitant medications included xantofyl, zeaxanthin (AREDS 2), vitamin d nos (MANUFACTURER UNKNOWN) and probiotics (MANUFACTURER UNKNOWN); all for unknown indication from an unknown date and unknown if ongoing. The patient previously took acetylsalicylic acid(ASPIRIN) and experienced drug allergy. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13Apr2021 at 18:00 the patient experienced flushing of the face and sudden racing heart. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event flushing of the face and sudden racing heart was recovered on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain, Menstruation irregular, Muscle spasms
Clinical narrative: I am experiencing an irregular menstrual cycle; Severe cramping in my lower back and lower abdomen; Severe cramping in "my" lower back and lower abdomen.; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 10Apr2021 at 09:00 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. Medical history included allergic to kiwi (fruit allergy). Prior to vaccination, the patient was not diagnosed with COVID -19. Concomitant medications included levonorgestrel (MIRENA) and salbutamol (ALBUTEROL); all used for an unknown indication, from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 12Apr2021 at 08:00, the patient experienced an irregular menstrual cycle. She normally had only spot if anything at all. Not this time and it was at least 2 weeks early. She also reported for severe cramping in patient lower back and lower abdomen. Normally she had nothing. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events irregular menstrual cycle and severe cramping in her lower back and lower abdomen was not resolved at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Chest discomfort, Headache, Nausea
Clinical narrative: Headache; Nausea; Heaviness in "my" chest; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 19Apr2021 at 13:30 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history and Concomitant medication was not reported. The patient previously received AMPICILLIN, on an unspecified date for an unknown indication and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UA7533) via an unspecified route of administration in the left arm on 19Apr2021 at 12:00 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. On 20Apr2021 at 07:00, the patient experienced headache, nausea, and heaviness in her chest. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache, nausea, and heaviness in chest were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Cough, Fatigue, Oropharyngeal pain
Clinical narrative: Cough; Chills; Fatigue; Sore throat; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0172) via an unspecified route of administration in the left arm on 25Apr2021 at 12:00 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included zolpidem tartrate (AMBIEN), alprazolam (XANAX), diphenhydramine / paracetamol / phenylpropanolamine hydrochloride (BENADRYL) and paracetamol (TYLENOL); for unknown indication from unknown dates and unknown if ongoing. The patient previously took morphine (MANUFACTURER UNKNOWN) for unknown indication on unknown date and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 04Apr2021 at 12:00 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. On 25Apr2021 at 13:30, the patient experienced cough, chills, fatigue and sore throat. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events cough, chills, fatigue and sore throat was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.